RoActemra launched for rheumatoid arthritis

Roche has launched RoActemra (tocilizumab) for use in combination with methotrexate (MTX) to treat moderate to severe active rheumatoid arthritis in adults with an inadequate response or intolerance to one or more DMARDs or TNF antagonists, or as monotherapy in these patients in case of MTX intolerance or where continued treatment with MTX is inappropriate.


To continue enjoying this article, please sign in. You can register for free for limited further access, or subscribe now for full access to all our content.

Sign In

Trouble signing in?

Reset password: Click here

Need help? Email us



  • Limited free articles a month 
  • Free email bulletins

Register Now

Subscribe now

Benefits include:

  • Full site access
  • Subscriber exclusive content
  • Exclusive bulletins

Choose a package